Heartland Advisors Inc. lowered its holdings in Cambrex Co. (NYSE:CBM) by 3.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 185,249 shares of the biotechnology company’s stock after selling 5,679 shares during the period. Heartland Advisors Inc. owned 0.56% of Cambrex worth $12,671,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the company. BlackRock Inc. grew its position in shares of Cambrex by 8.7% in the second quarter. BlackRock Inc. now owns 4,624,250 shares of the biotechnology company’s stock valued at $241,849,000 after purchasing an additional 370,806 shares during the period. Bank of New York Mellon Corp boosted its holdings in Cambrex by 3.8% in the second quarter. Bank of New York Mellon Corp now owns 1,471,966 shares of the biotechnology company’s stock valued at $76,982,000 after acquiring an additional 54,475 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Cambrex by 1.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,420,580 shares of the biotechnology company’s stock valued at $74,295,000 after acquiring an additional 13,858 shares during the last quarter. American Capital Management Inc. boosted its holdings in Cambrex by 0.3% in the third quarter. American Capital Management Inc. now owns 722,809 shares of the biotechnology company’s stock valued at $49,440,000 after acquiring an additional 2,333 shares during the last quarter. Finally, Boston Partners boosted its holdings in Cambrex by 3.2% in the second quarter. Boston Partners now owns 699,286 shares of the biotechnology company’s stock valued at $36,572,000 after acquiring an additional 21,399 shares during the last quarter.
A number of research analysts recently weighed in on CBM shares. Jefferies Financial Group started coverage on Cambrex in a report on Tuesday, September 25th. They issued a “buy” rating and a $75.50 target price on the stock. Robert W. Baird started coverage on Cambrex in a report on Thursday. They issued an “outperform” rating on the stock. First Analysis upgraded Cambrex from an “outperform” rating to a “strong-buy” rating and reduced their target price for the company from $73.00 to $63.00 in a report on Friday, November 9th. Finally, Zacks Investment Research upgraded Cambrex from a “hold” rating to a “strong-buy” rating and set a $73.00 target price on the stock in a report on Wednesday, August 8th. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Cambrex currently has a consensus rating of “Buy” and an average price target of $70.50.
In other Cambrex news, CEO Steven M. Klosk sold 20,000 shares of the business’s stock in a transaction dated Tuesday, October 23rd. The stock was sold at an average price of $54.76, for a total transaction of $1,095,200.00. Following the transaction, the chief executive officer now owns 103,328 shares in the company, valued at $5,658,241.28. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Steven M. Klosk sold 55,000 shares of the business’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $66.30, for a total value of $3,646,500.00. Following the transaction, the chief executive officer now owns 138,328 shares in the company, valued at approximately $9,171,146.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 84,510 shares of company stock worth $5,344,824. 2.42% of the stock is currently owned by insiders.
Shares of Cambrex stock opened at $47.29 on Friday. Cambrex Co. has a twelve month low of $44.92 and a twelve month high of $69.43. The firm has a market capitalization of $1.59 billion, a P/E ratio of 11.85, a PEG ratio of 1.71 and a beta of 2.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.41 and a current ratio of 4.54.
Cambrex (NYSE:CBM) last issued its earnings results on Thursday, November 8th. The biotechnology company reported $0.49 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.59 by ($0.10). Cambrex had a net margin of 22.67% and a return on equity of 22.20%. The firm had revenue of $104.62 million during the quarter, compared to analyst estimates of $122.04 million. During the same quarter in the previous year, the business posted $0.55 EPS. Cambrex’s revenue was down 7.1% compared to the same quarter last year. As a group, equities research analysts predict that Cambrex Co. will post 2.77 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/18/cambrex-co-cbm-stake-lowered-by-heartland-advisors-inc.html.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Featured Article: How does inflation affect different investments?
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.